Vsee Health regains Nasdaq compliance after equity increase
DUBLIN - Investment firm Citadel Group has disclosed a 1.8% ownership position in Avadel Pharmaceuticals plc, according to a regulatory filing published Friday.
The disclosure, made under Irish Takeover Panel rules, reveals Citadel holds 1,757,015 shares representing 1.8% of the pharmaceutical company, while also maintaining a short position of 2,198,064 shares or approximately 2.25% of the company.
The filing details extensive trading activity conducted on October 23, with Citadel executing numerous purchase and sale transactions of Avadel common stock at prices ranging primarily between $18.47 and $18.56 per share.
The disclosure also outlines Citadel's options positions, including both put and call options with various strike prices and expiration dates extending through January 2027.
Regulatory rules require investors to disclose positions when they reach or exceed 1% ownership in companies that could be involved in potential takeover situations.
The filing was made through the Regulatory Information Service as required under Rule 8.3 of the Irish Takeover Panel Act. Avadel Pharmaceuticals is listed on the Nasdaq exchange and is incorporated in Ireland.
This information is based on a regulatory disclosure statement filed by Citadel Group.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.